RNA Modification by m6A Methylation in Cardiovascular Disease.

Abstract

Cardiovascular disease is currently the leading cause of death worldwide, and its underlying regulatory mechanisms remain largely unknown. N6-Methyladenosine (m6A) RNA methylation is an epigenetic modification involved in the splicing, nuclear export, translational regulation, and degradation of RNA. After the initial identification of m6A RNA methylation in 1974, the rise of next-generation sequencing technology to detect m6A throughout the transcriptome led to its renewed recognition in 2012. Since that time, m6A methylation has been extensively studied, and its functions, mechanisms, and effectors (e.g., METTL3, FTO, METTL14, WTAP, ALKBH5, and YTHDFs) in various diseases, including cardiovascular diseases, have rapidly been investigated. In this review, we first examine and summarize the molecular and cellular functions of m6A methylation and its readers, writers, and erasers in the cardiovascular system. Finally, we discuss future directions for m6A methylation research and the potential for therapeutic targeting of m6A modification in cardiovascular disease.

• Authors: Jun Chen, Xiang Wei, Xin Yi, Ding-Sheng Jiang
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2021 Pg. 8813909 ( 2021) ISSN: 1942-0994 [Electronic] United States
• PMID: 34221238 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Jun Chen et al.

Topics

• Cardiovascular Diseases (genetics)
• Humans
• Methylation
• RNA Processing, Post-Transcriptional (genetics)